Omeros Corporation Reports Third Quarter 2026 Financial Results

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Third Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 16, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third q

Event · Earnings
Also in this documentBuyback · $30.5M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 16, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$OMER
Neutral
high confidence
Mentioned
$OMER
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$OMERNeutralMed
01

Why it matters

The quarter shows improving commercial traction (gross and net revenue growth, positive operating cash flow) and balance-sheet support (cash and note repurchases), but the EU EMA CHMP issued a negative opinion on the TA-TMA marketing authorization application after re-examination, creating a clear regulatory risk for future ex-US expansion.

02

Market read

Traders get a near-term fundamentals update (revenue growth, operating cash flow, cash position, note repurchases) plus a discrete EU regulatory negative that can reprice risk for the commercialization outlook.

03

What to watch

The non-cash derivative mark-to-market drove most GAAP loss; the more decision-relevant items are operating cash flow, NTAP/340B adoption, and the status/timing of any EU appeal or resubmission path.

Relevance 7/10Novelty 7/10Timing: after-hours filing, conference call scheduled for 4:30 p.m. ET
AlphAI · Earnings readOMER · Q3 2026 · ended 2026-09-30

YARTEMLEA net product sales reached $35,934 thousand in Q3 2026 and operating income turned positive at $4,501 thousand, while a $62.0 million non-cash derivative loss drove a GAAP net loss of $(57,356) thousand.

→Mixed quarter

Product revenue grew sequentially for a second period and operating income was positive, with operating cash flow of $13.3 million. The GAAP net loss of $(57,356) thousand, driven by a $62.0 million non-cash loss on the fair value of financial instruments, and a higher gross-to-net adjustment of 14.0% keep the quarter mixed. The company also disclosed a negative CHMP opinion in October 2026.

Revenue
$41.8M
29.6% q/q
YARTEMLEA (net product sales, the only product revenue line reported)
$35,934 thousand (Q3 2026); $74,356 thousand (nine months 2026)
26% q/q
EPS · non-GAAP
$0.06

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Gross YARTEMLEA revenue, Q3 2026other$41.8M29.6%–
Product sales, net, Q3 2026GAAP$35.93M26%–
Product sales, net, nine months 2026GAAP$74.36M––
Gross-to-net adjustment, Q3 2026other14.0%––
Cost of product sales, Q3 2026GAAP$826K––
Cost of product sales, nine months 2026GAAP$2.21M––
Research and development, Q3 2026GAAP$16.06M––
Research and development, nine months 2026GAAP$43.22M––
Selling, general and administrative, Q3 2026GAAP$14.55M––
Selling, general and administrative, nine months 2026GAAP$41.77M––
R&D and SG&A combined, Q3 2026 (as printed in MD&A)GAAPapproximately $30.6 million––
Total costs and expenses, Q3 2026GAAP$31.43M––
Total costs and expenses, nine months 2026GAAP$87.20M––
Income (loss) from operations, Q3 2026GAAP$4.50M––
Income (loss) from operations, nine months 2026GAAP−$12.85M––
Interest and other income, Q3 2026GAAP$1.87M––
Interest and other income, nine months 2026GAAP$7.97M––
Interest expense, net of remeasurement adjustments and other, Q3 2026GAAP−$6.22M––
Interest expense, net of remeasurement adjustments and other, nine months 2026GAAP−$19.70M––
Net gain (loss) on change in fair value of financial instruments, Q3 2026GAAP−$62.02M––
Net gain (loss) on change in fair value of financial instruments, nine months 2026GAAP$22.57M––
Loss on early extinguishment of 2029 Notes, Q3 2026GAAP−$1.91M––
Loss on early extinguishment of 2029 Notes, nine months 2026GAAP−$3.80M––
Net loss from continuing operations, Q3 2026GAAP−$63.83M––
Net loss from continuing operations, nine months 2026GAAP−$5.94M––
Net income (loss) from discontinued operations, Q3 2026GAAP$6.47M––
Net income (loss) from discontinued operations, nine months 2026GAAP$17.88M––
GAAP net income (loss), Q3 2026GAAP−$57.36M––
GAAP net income (loss), nine months 2026GAAP$11.94M––
GAAP net income (loss) per share, basic, Q3 2026GAAP$(0.79)––
GAAP net income (loss) per share, diluted, nine months 2026GAAP$0.13––
Non-GAAP adjusted net income (loss), Q3 2026non-GAAP$4.66M––
Non-GAAP adjusted net income (loss), nine months 2026non-GAAP−$10.64M––
Non-GAAP adjusted net income (loss) per share, basic, Q3 2026non-GAAP$0.06––
Non-GAAP adjusted net income (loss) per share, basic, nine months 2026non-GAAP$(0.15)––
Operating cash flow, Q3 2026 (not labelled GAAP in filing)other$13.3M––
Cash and short-term investments at September 30, 2026other$95.3M––

Segments

SegmentRevenueq/qy/y
YARTEMLEA (net product sales, the only product revenue line reported)Net revenue increased 26% to $35.9 million from $28.5 million in the second quarter. The company states that the gross-to-net adjustment rose to 14.0% from 11.5% because of higher purchases by 340B Drug Pricing Program entities, consistent with its goals of increasing outpatient utilization and expanding its customer base.$35,934 thousand (Q3 2026); $74,356 thousand (nine months 2026)26%–

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Capital returns

  • In June and July 2026 the company entered into privately negotiated agreements to repurchase $30.5 million aggregate principal amount of 2029 Notes for a total purchase price of $60.2 million, plus accrued and unpaid interest of $0.2 million. Both transactions closed in July 2026.
  • Approximately $40.3 million aggregate principal amount of 2029 Notes remains outstanding after the repurchases.
  • The company states that the repurchases eliminated approximately $8.6 million in future interest payment obligations and reduced the shares issuable on conversion of the 2029 Notes by 4.9 million shares, from 11.4 million to 6.5 million.
  • During the first half of 2026 the company repurchased more than 843,000 shares of common stock at a volume-weighted average price of $11.70 per share. The company states that these transactions together reduced outstanding or potentially issuable shares by 5.8 million year to date.
  • No dividend information is provided in the filing.

What drove it

  • YARTEMLEA gross revenue rose to $41.8 million from $32.2 million, and net revenue rose 26% to $35.9 million from $28.5 million, per the company.
  • The company states that the higher gross-to-net adjustment was driven by higher purchases by 340B-covered entities, consistent with its goal of increasing outpatient utilization and expanding its customer base.
  • The company states that the GAAP net loss of $(57,356) thousand included a non-cash loss of $62.0 million primarily related to mark-to-market adjustments of a derivative associated with the 2029 Notes.
  • Income from operations was $4,501 thousand in the third quarter compared with $0.1 million in the second quarter, per the release.
  • Interest and other income fell to $1.9 million from $4.6 million. The company states the $2.7 million decrease was primarily the result of a reimbursement from Novo for the transfer of zaltenibart inventory recorded in the second quarter.
  • The company states that the NTAP designation for YARTEMLEA became effective on October 1, 2026, providing eligible hospitals up to $287,079 in additional Medicare reimbursement per eligible inpatient case.

Concerns

  • The GAAP net loss of $(57,356) thousand, or $(0.79) per share, reflects a $62.0 million non-cash loss from the change in fair value of financial instruments, compared with a $(8,822) thousand loss in the prior-year quarter.
  • The gross-to-net adjustment rose to 14.0% from 11.5% in the second quarter, as the company explains through higher 340B purchases.
  • In October 2026 the CHMP issued a negative opinion on the MAA for narsoplimab in TA-TMA following re-examination of its June 2026 negative opinion.
  • Total shareholders' deficit was $(89,973) thousand at September 30, 2026.
  • Interest and other income declined to $1,867 thousand from $4.6 million in the prior quarter. The company attributes the decline primarily to a Novo reimbursement recorded in the second quarter.
  • Receivables increased to $23,096 thousand from $10,917 thousand at December 31, 2025.

What to watch

  • Whether YARTEMLEA revenue continues to grow in the fourth quarter, which the CEO states has continued.
  • Trend in the gross-to-net adjustment as 340B participation expands, following the 14.0% level in Q3 2026.
  • Effect of the NTAP designation effective October 1, 2026, and of favorable Medicare outpatient reimbursement for 340B-acquired YARTEMLEA beginning January 1, 2027.
  • Mark-to-market swings in the derivative associated with the 2029 Notes, which drove the Q3 non-cash loss.
  • Initiation timing of the two YARTEMLEA studies in ARDS and pediatric TA-TMA prevention, anticipated in late 2026 or early 2027.
  • Start of OMS527 enrollment in Q1 2027, subject to the nonclinical study the company is conducting for FDA.
  • Zaltenibart Phase 3 initiation by Novo, and the expected near-term milestone payments of up to $100 million.
  • Completion of Novo transition services, which the company expects by mid-2027.
  • Planned start of the OncotoX-AML Phase 1b trial in late 2027.

Balance sheet and cash flow

  • Cash and cash equivalents: $5,070 thousand at September 30, 2026 versus $9,660 thousand at December 31, 2025.
  • Short-term investments: $90,180 thousand at September 30, 2026 versus $162,144 thousand at December 31, 2025.
  • Receivables: $23,096 thousand at September 30, 2026 versus $10,917 thousand at December 31, 2025.
  • Total current assets: $150,893 thousand at September 30, 2026 versus $215,667 thousand at December 31, 2025.
  • Total assets: $248,095 thousand at September 30, 2026 versus $325,632 thousand at December 31, 2025.
  • 2026 Notes, net: nil at September 30, 2026 versus $17,063 thousand at December 31, 2025.
  • 2029 Notes, non-current, net: $31,891 thousand at September 30, 2026 versus $51,364 thousand at December 31, 2025.
  • 2029 Notes embedded derivative, non-current: $101,136 thousand at September 30, 2026 versus $157,171 thousand at December 31, 2025.
  • OMIDRIA royalty obligation, non-current: $130,624 thousand at September 30, 2026 versus $147,319 thousand at December 31, 2025.
  • Total shareholders' deficit: $(89,973) thousand at September 30, 2026 versus $(121,231) thousand at December 31, 2025.
  • Operating cash flow of $13.3 million was generated in the third quarter of 2026. The company states it generated positive operating cash flow in consecutive quarters.

Analysis

Omeros reported third quarter 2026 results in which YARTEMLEA, its approved product for stem cell transplant-associated thrombotic microangiopathy, generated gross revenue of $41.8 million and net product sales of $35,934 thousand. The company states that gross revenue rose 29.6% from $32.2 million in the second quarter and that net revenue rose 26% from $28.5 million. Product sales in the prior-year quarter are shown as a dash in the statements, so no year-over-year growth rate is printed for the product line. Total costs and expenses were $31,433 thousand, compared with $26,392 thousand a year earlier. Income from operations was $4,501 thousand, against $0.1 million in the second quarter, and nine-month operating loss narrowed to $(12,846) thousand from $(93,715) thousand.

The gross-to-net adjustment widened to 14.0% from 11.5%. The company attributes the increase to higher purchases by 340B-covered entities, which it links to its goals of increasing outpatient utilization and expanding its customer base. Cost of product sales was $826 thousand in the quarter. Gross margin is not printed in the filing, so the reader cannot see product-level profitability directly from the document.

Below the operating line, the quarter was dominated by a non-cash item. The net loss from continuing operations was $(63,825) thousand, mainly because of a $(62,020) thousand change in the fair value of financial instruments. GAAP net loss was $(57,356) thousand, or $(0.79) per share, after $6,469 thousand of income from discontinued operations. The company's non-GAAP adjusted net income excludes the remeasurement and was $4,664 thousand, or $0.06 per share, against $1,785 thousand in the second quarter. Interest and other income fell to $1,867 thousand from $4.6 million, which the company attributes primarily to a Novo reimbursement recorded in the second quarter.

On the balance sheet, cash and short-term investments were $95.3 million at September 30, 2026, and operating cash flow was $13.3 million for the quarter. Total shareholders' deficit narrowed to $(89,973) thousand from $(121,231) thousand at December 31, 2025, and the 2029 Notes embedded derivative fell to $101,136 thousand from $157,171 thousand. The company repurchased $30.5 million principal of 2029 Notes for $60.2 million plus accrued interest, leaving about $40.3 million outstanding. These repurchases reduced potentially issuable shares by about 4.9 million, and the company reports $8.6 million of eliminated scheduled interest payments.

The filing gives no quantitative guidance for the coming period. The forward-looking points are qualitative: NTAP became effective October 1, 2026, Medicare outpatient reimbursement for 340B-acquired YARTEMLEA is expected to be favorable from January 1, 2027, and several pipeline milestones are targeted for late 2026 through 2027. Against these, the company disclosed a negative CHMP opinion for narsoplimab in TA-TMA in October 2026, which is a material regulatory setback for the European opportunity.

Management, verbatim

YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow.

Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer

As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of YARTEMLEA.

Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer

Not in the filing

stated, not guessed
  • Gross margin or gross profit on product sales: not printed in the filing.
  • Financial guidance for revenue, gross margin, operating expenses or tax rate: none provided in the filing.
  • Prior-year gross YARTEMLEA revenue and prior-year gross-to-net adjustment: not printed.
  • Prior-quarter (Q2 2026) separate R&D and SG&A figures: only their combined total is printed in MD&A.
  • Prior-quarter cost of product sales, total costs and expenses, and SG&A: not printed.
  • Year-over-year and quarter-over-quarter percentage changes for operating income, interest, net loss and per-share lines: not printed.
  • Prior-quarter operating cash flow: not printed, so the statement of consecutive positive quarters is company commentary only.
  • Operating cash flow basis (GAAP or non-GAAP): not labelled in the filing.
  • Dividend information: not in the filing.
  • Consensus estimates, analyst expectations and share-price reaction: not in the filing and not provided.
  • Discrepancy: the highlights section gives the Q2 2026 non-cash gain as $11.5 million, while the Financial Results section gives $11.4 million; the reconciliation shows 11,447 thousand. The $11.4 million figure is used in the table row, and the discrepancy is noted here.
  • Interest expense (net) and remeasurement lines in the schedule are presented with mixed signs; the 2025 comparatives are copied as printed.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Omeros furnished its Q3 2026 financial results via SEC 8-K, alongside updates on YARTEMLEA commercialization, reimbursement changes, and pipeline progress.

Company-level read

Ticker impact

$OMERNeutralHigh confidence
Context

Omeros reports Q3 2026 results, including YARTEMLEA revenue growth, cash balance, and a negative CHMP opinion for narsoplimab in TA-TMA.

Expected impact

Likely mixed reaction, with support from YARTEMLEA growth and cash flow offset by renewed EU regulatory risk.

Evidence & confidence

The filing provides both operating positives (revenue growth, positive operating cash flow, NTAP effective) and a concrete negative regulatory development (CHMP negative opinion after re-examination).

Market effects

Reinforces investor focus on reimbursement-driven adoption and EU regulatory outcomes for rare-disease biotech revenue streams.

EU regulatory decision risk may affect sentiment toward other transplant/rare-disease therapies seeking CHMP support.

Highlights how reimbursement policy (NTAP, 340B) can materially influence near-term cash generation for specialty biopharma.

Counterpoint

Traders may over-weight the CHMP negative opinion, while the company emphasizes continued sales growth and US reimbursement tailwinds that could dominate near-term fundamentals.

Key entities

  • Omeros Corporation

    Nasdaq-listed biotech reporting Q3 2026 results and updates on YARTEMLEA and its MASP-2/MASP-3 platform.

  • YARTEMLEA (narsoplimab-wuug)

    Approved TA-TMA treatment whose Q3 revenue and reimbursement dynamics are central to the quarter’s operating narrative.

  • European Medicines Agency (EMA) CHMP

    Issued a negative opinion on Omeros’ TA-TMA marketing authorization application after re-examination.

  • Novo

    Develops zaltenibart, a MASP-3 inhibitor antibody acquired from Omeros, with milestone eligibility referenced.

Every OMER earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$OMERMed

OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares

Omeros (OMER) shares are down, heading for their worst day in 18 months. The company delayed Q4 and 2027 sales guidance, citing uncertainty. A clinical trial for OMS527 was postponed to 2027 due to delays in acquiring study animals. Despite this, retail sentiment on Stocktwits turned bullish, focusing on Yartemlea's launch and a partnership with Novo Nordisk. OMER stock is down 22% year-to-date.

$OMERMed

Omeros (OMER) Q3 2026 Earnings Call Transcript

Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.

$OMERMed

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 10.4% in after-hours trading after reporting Q3 2026 results. The company reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a $62.0 million non-cash loss. Adjusted EPS of $0.06 beat estimates, and revenue exceeded expectations. A negative opinion from the European Medicines Agency on narsoplimab also weighed on sentiment.

$OMERMedAI 8/10

Omeros falls 10% despite revenue beat

Omeros (NASDAQ:OMER) reported Q3 revenue of $41.8M, beating estimates, but shares fell 10% due to a widened GAAP net loss of $57.4M. Adjusted earnings were $0.06 per share, exceeding expectations. YARTEMLEA sales grew 30% sequentially. The company held $95.3M in cash as of Q3 2026.